Ascendis Pharma A/S granted 14,060 warrants to employees on July 14, 2026, with an exercise price of $265.57 per share. The warrants vest in stages, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting monthly over the following 36 months. Ascendis Pharma A/S is a biotechnology company focused on oncolytic and oncolytic-related therapies.
